Metanoia Press · In preparation
N,N-Dimethyltryptamine is the strangest member of the classic family. Vaporized, it acts within seconds and is gone in minutes — yet people describe those minutes as among the most vivid experiences of their lives. It is also, remarkably, a molecule the human body appears to make in trace amounts, and one that occurs across an enormous range of plants. Our forthcoming book gives DMT the same whole-system treatment we gave the mushroom: the chemistry, the brain, the tradition, and the honest edges.
What the Book Will Cover
A simple tryptamine built from tryptophan — why it's inactive by mouth alone, and how the ayahuasca brew solves that problem.
A potent agonist at the 5-HT2A serotonin receptor, the same doorway shared by psilocybin and LSD — and what "breakthrough" states reveal about perception.
From Amazonian snuffs to the visionary lineage — and the enduring puzzle of a psychedelic the body itself seems to produce.
Intravenous and inhaled DMT now in early trials for depression — the science of a very short-acting medicine.
DMT works, like most of the family, primarily through the brain's 5-HT2A serotonin receptor. Taken by mouth on its own it does almost nothing — the enzyme monoamine oxidase in the gut breaks it down before it can act. That single pharmacological fact is the hinge of the whole story: combine DMT with a MAO-inhibiting plant and it becomes orally active, which is exactly what the Amazonian ayahuasca brew does.
Its clinical chapter is just opening. An intravenous DMT candidate reported a rapid antidepressant signal in an early-phase trial, published in a leading medical journal — promising, small, and early. As always, we hold the promise and the uncertainty together.
Reliability: the receptor pharmacology is well established (strong); the clinical evidence is early-stage and preliminary. Full sources will accompany the finished book.